"Global COPD and Asthma
Devices Market - Size, Industry Analysis, Trends, Opportunities, Growth and
Forecast, 2013 - 2020", the global COPD and asthma devices market would
reach $34.3 billionby 2020, registering a CAGR of 4.5% during 2014 - 2020.
Considering the growth and market size, Dry Powder Inhalers (DPIs) will be the
most lucrative market segment of the COPD and Asthma devices (inhalers) market
by 2020.
Metered Dose Inhalers (MDIs) are
the largest revenue generating segment currently and would maintain the stand
till 2020.The need for urgency in medication and portability of the drug
delivery devices will drive the growth for COPD and Asthma devices. Despite
notable advantages of the COPD and Asthma devices, some factors such as
environmental concerns are likely to impede the growth of COPD and Asthma
devices market. It is observed that the inhalers, particularly the MDIs,
release environmentally-hazardous gases, namely chlorofluorocarbon (CFC) and
hydrofluoroalkanes (HFA), which is negatively impacting growth of the MDIs
segment.
Consumption pattern will shift to
better alternatives, namely the DPIs. The Soft Mist Inhalers (SMIs), which are
another type of inhalers, deliver metered dosage of medication as a soft mist.
Such form of drug delivery is ~65% to 80% more efficacious than its peers and
will eventually display higher growth as compared to its peers.
Nebulizers, electric or battery
powered machines that dispense medication as a fine mist, are ideal for home
healthcare set-up for debilitated patients, geriatrics and children. Nebulizers
segment thus holds about 13% of the global COPD and Asthma devices market;
however, the nebulizers market is forecast to have diminishing growth through
2020 as nebulizers are rendered ineffectual, as POC or portable COPD and Asthma
devices due to its larger set up.
Key findings of the study:
- Drug powder inhalers (DPIs) segment will grow at a CAGR of 5.3% during the forecast period, fastest among all
- North American market would be one of the most lucrative markets, in terms of growth
- European market for COPD and asthma devices would reach $10 billion by 2020, with the CAGR of 4.8%
- Within the nebulizers segment markets, compressor nebulizers would be most lucrative, growing at 7% CAGR during the forecast period and compressor nebulizers would garner 81.5% market share by 2020
- Specific focus to achieve product differentiation and thus gain competitive advantage drives the development of new product variants of COPD and Asthma devices. In accordance to the afore-mentioned trend, the market has witnessed steady stream of product launch. Key product manufacturing companies profiled in the report include GlaxoSmithKline Plc, Novartis AG, Merck & Co., Inc., AstraZeneca Plc, Philips Healthcare, 3M Health Care, Allied Healthcare Products Inc., Sunovion Pharmaceuticals Inc., GF Healthcare Products, Smith Medicals, Lincare Holdings Inc. and Baxter International.
Spanning over 130 pages, 57 Tables and 23
Figures “Global COPD and Asthma Devices
Market (Product Types and Geography) - Size, Share, Global Trends, Company
Profiles, Demand, Insights, Analysis, Research, Report, Opportunities,
Segmentation and Forecast, 2013 - 2020” report Covering Introduction,
Executive Summary, Market Overview, Global Copd And Asthma Devices Market By
Product Type, 2013-2020, $Million, Global Copd And Asthma Devices Market By
Geography, 2013-2020, $Million, Company Profiles. This report Covered These
Companies - GlaxoSmithKline Plc, Novartis AG, Merck & Co., Inc., Philips
Healthcare, AstraZeneca Plc, 3M Health Care, Allied Healthcare Products Inc.,
GF Health Products Inc., Sunovion Pharmaceuticals Inc., Smith Medicals, Lincare
Holdings Inc., Baxter International.
Know more
about this report at – http://mrr.cm/4kS
Find all Medical
Devices
Reports at: http://www.marketresearchreports.com/medical-devices
No comments:
Post a Comment
Note: only a member of this blog may post a comment.